ABSTRACT
Purpose Radiomics, the objective study of non-visual features in clinical imaging, has been useful in informing decisions in clinical oncology. However, radiomics currently lacks the ability to characterize the overall topological structure of the data. This niche can be filled by persistent homology, a form of topological data analysis that analyzes high-level structure. We hypothesized that persistent homology could be applied to lung tumor scans and analyze clinical outcomes.
Methods We obtained segmented computed tomography lung scans (n = 565) from the NSCLC-Radiomics and NSCLC-Radiogenomics datasets in The Cancer Imaging Archive. For each scan, a cubical complex filtration based on Hounsfield units was generated. We calculated a feature curve that plotted the number of 0 dimensional topological features against each Hounsfield unit. This curve’s first moment of distribution was utilized as a summary statistic to predict survival in a Cox proportional hazards model.
Results After controlling for tumor image size, age, and stage, the first moment of the 0D topological feature curve was associated with poorer survival (HR = 1.118; 95% CI = 1.026-1.218; p = 0.01). The patients in our study with the lowest first moment scores had significantly better survival (1238 days; 95% CI = 936-1599) compared to the patients with the highest first moment scores (429 days; 95% CI = 326-601; p = .0015).
Conclusions We have shown that persistent homology can generate useful clinical correlates from tumor CT scans. Our 0-dimensional topological feature curve statistic predicts survival in lung cancer patients. This novel statistic may be used in tandem with standard radiomics variables to better inform clinical oncology decisions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for this project was provided by the Case Comprehensive Cancer Center medical student summer research training grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A Public Database from The Cancer Imaging Archive was used
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* evs27{at}case.edu
We updated the Methods section to be more clear about our process. We increased the size of all figures and figure elements to improve readability.
Data Availability
All data and code to perform the analyses can be found at https://github.com/eashwarsoma/TDA-Lung-Phom-Reproducible.
